Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Liquidia Corporation, Amneal Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Liquidia Corporation, Amneal Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Liquidia Corporation, Amneal Pharmaceuticals and Inc.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Latest Pharmaceuticals and Liquidia Corporation, Amneal Pharmaceuticals, Inc. Stock News
As of August 12, 2025, Liquidia Corporation had a $2.1 billion market capitalization, compared to the Pharmaceuticals median of $358.3 million. Liquidia Corporation’s stock is NA in 2025, NA in the previous five trading days and up 111.78% in the past year.
Currently, Liquidia Corporation does not have a price-earnings ratio. Liquidia Corporation’s trailing 12-month revenue is $14.1 million with a -980.5% net profit margin. Year-over-year quarterly sales growth most recently was 3.3%. Analysts expect adjusted earnings to reach $-1.400 per share for the current fiscal year. Liquidia Corporation does not currently pay a dividend.
Currently, Amneal Pharmaceuticals, Inc.’s price-earnings ratio is 820.0. Amneal Pharmaceuticals, Inc.’s trailing 12-month revenue is $2.9 billion with a 0.1% net profit margin. Year-over-year quarterly sales growth most recently was 3.2%. Analysts expect adjusted earnings to reach $0.767 per share for the current fiscal year. Amneal Pharmaceuticals, Inc. does not currently pay a dividend.
How We Compare Liquidia Corporation, Amneal Pharmaceuticals and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Liquidia Corporation, Amneal Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
Liquidia Corporation, Amneal Pharmaceuticals and Inc. Growth Grades
| Company | Ticker | Growth |
| Liquidia Corporation | LQDA |
D |
| Amneal Pharmaceuticals, Inc. | AMRX |
A |
The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.
In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.
The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.
Liquidia Corporation has a Growth Score of 30, which is Weak.
Amneal Pharmaceuticals, Inc. has a Growth Score of 92, which is Very Strong.
The Growth Grade Winner: Amneal Pharmaceuticals, Inc.
As you can clearly see from the Growth Grade breakdown above, Amneal Pharmaceuticals, Inc. has a more attractive growth grade than Liquidia Corporation. For investors who focus solely on how a company is growing relative to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.
Liquidia Corporation, Amneal Pharmaceuticals and Inc.’s Quality Grades
| Company | Ticker | Quality |
| Liquidia Corporation | LQDA |
F |
| Amneal Pharmaceuticals, Inc. | AMRX |
B |
Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.
The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.
The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.
Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.
Liquidia Corporation has a Quality Score of 4, which is Very Weak.
Amneal Pharmaceuticals, Inc. has a Quality Score of 80, which is Strong.
The Quality Grade Winner: Amneal Pharmaceuticals, Inc.
As you can clearly see from the Quality Grade breakdown above, Amneal Pharmaceuticals, Inc. has a better overall quality grade than Liquidia Corporation. For investors who are looking for companies with higher quality than others in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.
Liquidia Corporation, Amneal Pharmaceuticals and Inc.’s Estimate Revisions Grades
| Company | Ticker | Earnings Estimate |
| Liquidia Corporation | LQDA |
F |
| Amneal Pharmaceuticals, Inc. | AMRX |
A |
Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).
Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.
Liquidia Corporation has a Earnings Estimate Score of 20, which is Very Negative.
Amneal Pharmaceuticals, Inc. has a Earnings Estimate Score of 84, which is Very Positive.
The Earnings Estimate Revisions Grade Winner: Amneal Pharmaceuticals, Inc.
As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Amneal Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Liquidia Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.
Don’t Forget Your Free Special Report on How A+ Grades Can Help You Make Investment Decisions
Other Liquidia Corporation, Amneal Pharmaceuticals and Inc. Grades
In addition to Quality, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Momentum.
Invest with Confidence with A+ Investor
AAII’s expansive and robust screening tools like A+ Investor help investors make confident decisions.
Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.
Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.
These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Liquidia Corporation, Amneal Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.
So, Which Is the Better Investment, Liquidia Corporation, Amneal Pharmaceuticals or Inc. Stock?
Overall, Liquidia Corporation stock has a Growth Score of 30, Estimate Revisions Score of 20 and Quality Score of 4.
Amneal Pharmaceuticals, Inc. stock has a Growth Score of 92, Estimate Revisions Score of 84 and Quality Score of 80.
Comparing Liquidia Corporation, Amneal Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.
Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.
A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.
